Luigi Melcarne
A5004327640- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- COVID-19 Clinical Research Studies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders
- Health Systems, Economic Evaluations, Quality of Life
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Stoma care and complications
- COVID-19 and Mental Health
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Diagnosis and treatment of tuberculosis
- Gastrointestinal disorders and treatments
- Colorectal Cancer Treatments and Studies
- Helicobacter pylori-related gastroenterology studies
- Pancreatitis Pathology and Treatment
- Immunodeficiency and Autoimmune Disorders
- Liver Disease and Transplantation
- Biliary and Gastrointestinal Fistulas
- Health, Technology, Consumer Behavior
- Glycogen Storage Diseases and Myoclonus
Centro de Investigación Biomédica en Red
2019-2025
Institute of Research and Innovation Parc Tauli
2023-2025
Deleted Institution
2016-2024
Corporació Sanitària Parc Taulí
2016-2024
Universitat Autònoma de Barcelona
2023-2024
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2021
Hospital Clínic de Barcelona
2019
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019
Abbott (Sweden)
2018
Takeda (United States)
2018
Objectives The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate prevalence symptoms and post-COVID-19 disorders gut–brain interaction after hospitalisation for SARS-CoV-2 infection. Design GI-COVID-19 is a prospective, multicentre, controlled study. Patients with without diagnosis were evaluated hospital admission 1, 6 12 months post hospitalisation. Gastrointestinal symptoms, anxiety depression assessed using validated...
INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated their occurrence, variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients COVID-19 diagnosis were recruited hospital admission asked for after month, using validated Symptom Rating Scale...
Abstract Background Data of telemonitoring costs in inflammatory bowel disease (IBD) are scarce and restricted to a few centres. We evaluated healthcare indirect IBD compared standard care after 52 weeks on nationwide scale. Methods A 2-arm randomized multicenter study was performed 24 Spanish centers. included adult patients with who initiated therapy immunosuppressant or biological agents. Patients ileorectal/ileo-pouch anal anastomosis, stoma, active perianal no Internet access were...
ABSTRACT Background The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has highlighted the potential exacerbation of gastrointestinal symptoms in patients with disorders gut‐brain interaction (DGBIs). However, distinct symptom trajectories and psychological burden post‐COVID‐19 DGBIs compared pre‐existing irritable bowel (IBS)/functional dyspepsia (FD) non‐DGBI controls remain poorly understood. Objectives To examine long‐term progression comorbidities DGBI, IBS/FD...
A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety intravenous re-induction in Crohn's disease who have lost response treatment.This is a retrospective, observational, multicenter study. Treatment measured at week 8 16; clinical remission defined when Harvey-Bradshaw Index ≤4 points, as decrease ≥3 points index compared baseline. Adverse events treatment decisions after were also collected.Fifty-three...
Background Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to more efficient. Objective This study aims compare the remission time and quality of life patients with active IBD managed through versus TECCU (Telemonitoring Crohn Disease Ulcerative Colitis) app. Methods A 2-arm, randomized, multicenter trial a design was conducted across 24 hospitals...
ABSTRACT Background Exposure to COVID‐19 has been shown previously be associated with a higher risk for irritable bowel syndrome (IBS). This study aimed better explain this relationship using mediation analysis. Methods post hoc analysis of multicenter cohort includes 623 patients and without infection. All participants completed the ROME IV criteria, gastrointestinal symptom rating scale (GSRS), hospital anxiety depression (HADS) over 1 year. Mediation utilized PROCESS macro Baron Kenny's...
Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn's disease (CD). However, more data are necessary on effectiveness bio-naïve patients real-life studies.The aim our study was to evaluate with CD refractory or intolerant conventional therapy without previous exposure biological drugs.We performed a nationwide, observational, retrospective, multicentre including CD, which used as first drug.The corticosteroid-free clinical response remission were analysed at...
We aim to describe the incidence and source of contagion COVID-19 in patients with IBD, as well risk factors for a severe course long-term sequelae. This is prospective observational study IBD included ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up 12 months. Results were compared data general population (National Centre Epidemiology Catalonia). A total 482 identified. Twenty-eight percent infected work environment, 48% by intrafamilial transmission, despite...
Few recent data on the epidemiology of inflammatory bowel disease (IBD) are available, especially in Southern Europe.To evaluate prevalence, incidence and mortality IBD Catalonia during period 2011-2016.Data were obtained from Catalan Health Surveillance System (CHSS). Crude prevalence rates calculated for all population. Trends age-sex-adjusted also estimated, logistic regression was used to calculate adjusted odds ratio (OR). Data Crohn's (CD) ulcerative colitis (UC) analyzed...
The impact of biologics on the risk postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack evidence more relevant for ustekinumab and vedolizumab.To evaluate PC.A retrospective study was performed 37 centres. Patients treated with within 12 weeks before surgery were considered "exposed". exposure 30-day PC infections assessed by logistic regression propensity score-matched analysis.A total 1535 surgeries 1370 patients. Of them, 711...
Background and Aims: Data from clinical trials suggest that biological drugs may improve the outcomes in Crohn’s disease (CD) by reducing need for surgery or hospitalization. The aim of this study is to evaluate time-trends use other treatments CD, its relationship with Catalonia. Materials Methods: All patients CD included Catalan Health Surveillance System (containing data on a population more than 7.5 million) 2011 2017 were identified. exposures different inflammatory bowel retrieved...
Retrospective studies suggest that coronavirus disease (COVID-19) commonly involves gastrointestinal (GI) symptoms and complications. Our aim was to prospectively evaluate GI manifestations in patients hospitalized for COVID-19. This international multicentre prospective cohort study recruited COVID-19 at 31 centres Spain, Mexico, Chile, Poland, between May September 2020. Patients were followed-up until 15 days post-discharge completed comprehensive questionnaires assessing A descriptive...
Background: Inflammatory bowel disease (IBD) has a major economic impact on healthcare costs. Objectives: The aim of this study was to evaluate the current expenditure associated with IBD in population-wide Catalonia. Design: Retrospective observational study. Methods: All patients included Catalan Health Surveillance System (CHSS) were considered eligible. CHSS compiles data more than 7 million individuals 2020 (34,823 IBD). Data use resources and its extracted applying International...
Spontaneous bacterial peritonitis is an infectious complication with a negative impact on survival of patients cirrhosis.To analyze the short- and long-term after first episode associated prognostic factors.This was retrospective, multicenter study admitted to hospital for spontaneous between 2008 2013. Independent variables related mortality were analyzed by logistic regression. The power Child Pugh Score, Model End-Stage Liver Disease (MELD) Charlson index ROC curve.A total 159 enrolled,...
(1) Scant information is available concerning the characteristics that may favour acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, aim this study was to assess these differences between infected and noninfected IBD. (2) This nationwide case−control evaluated (cases) without (controls) during period March−July 2020 included ENEIDA GETECCU. (3) A total 496 cases 964 controls from 73 Spanish centres were included. No found basal controls. Cases had higher...
Running is popular. Ischemic colitis has been reported in marathon runners. We present a case of an amateur runner who developed ischemic after relatively short run.
Retrospective studies suggest that coronavirus disease (COVID-19) commonly involves gastrointestinal (GI) symptoms and complications. Our aim was to prospectively evaluate GI manifestations in patients hospitalized for COVID-19. This international multicentre prospective cohort study recruited COVID-19 at 31 centres Spain, Mexico, Chile, Poland, between May September 2020. Patients were followed-up until 15 days post-discharge completed comprehensive questionnaires assessing A descriptive...
Thiopurines are an effective treatment for the maintenance of remission in inflammatory bowel disease (IBD). They can present adverse effects (AEs), with myelotoxicity being most relevant. This study aims to determine incidence AEs related starting thiopurines our centre. Retrospective study. The patients that were started on between January 2016 and June 2020 registered, a two-year follow-up. mean standard deviation used describe quantitative variables, percentages confidence intervals...
Abstract Background Ustekinumab (UST) is a monoclonal antibody that inhibits the p40 subunit of IL-12 and IL-23, approved for treatment Crohn's Disease (CD) Ulcerative Colitis (UC). Its administration intravenous during induction subcutaneous maintenance. Several studies have assessed efficacy reinduction intensification this in patients with loss response. However, there are few evaluating effectiveness UST The aim study to evaluate safety maintenance Inflammatory Bowel (IBD). Methods...